Aug 2, 2024, 00:52
$RAC announces conclusion of an investigator-sponsored trial of bisantrene – Race Oncology
Race Oncology made the following post on X:
“$RAC is pleased to announce the successful conclusion of an investigator-sponsored Phase 1b/2 trial of bisantrene, with trial results showing the drug, in combination with clofarabine and fludarabine, has achieved its primary endpoint for efficacy.
More.”
Source: Race Oncology/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 18, 2024, 23:35
Sep 18, 2024, 23:27
Sep 18, 2024, 23:22
Sep 18, 2024, 23:19
Sep 18, 2024, 23:11
Sep 18, 2024, 23:03
Sep 18, 2024, 22:46